Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma

PHASE2TerminatedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

April 16, 2007

Primary Completion Date

May 19, 2008

Study Completion Date

December 25, 2009

Conditions
Multiple Myeloma
Interventions
DRUG

LBH589

Trial Locations (29)

19718

Christiana Care, Newark

27157

Wake Forest, Winston-Salem

27710

Duke, Durham

30322

Emory University, Atlanta

33612

Moffitt Cancer Center, Tampa

37203

Sarah Canon Research Center, Nashville

37212

Vanderbilt, Nashville

44109

Metrohealth, Cleveland

46203

Indiana University, Indianapolis

48109

University of Michigan, Ann Arbor

60612

Rush University, Chicago

60637

University of Chicago, Chicago

63110

Washington University, St Louis

78258

CTRC, San Antonio

80218

Rocky Mountain Cancer Center, Denver

85259

Mayo Clinic, Scottsdale

91010

City of Hope, Duarte

94143

UCSF, San Francisco

94305

Stanford, Stanford

94704

Aptium Oncology, Berkeley

52240-1515

University of Iowa, Iowa City

02115

Dana Farber, Boston

07456

Hackensack University, Hackensack

75390-9179

University of Texas Southwestern, Dallas

Unknown

Novartis investigative Site, Berlin

Novartis Investigative Site, Heidelberg

Novartis Investigative Site, Kiel

Novartis Investigative Site, Starnberg

Novartis Investigative Site, Würzburg

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY